TCTMD - tctmd.com
There is a growing recognition of the prevalence and outcomes associated with tricuspid regurgitation, whether in isolation or with concomitant diseases. This program will focus on defining the burden of disease, outlining current guideline directed medical therapy and discussing the recent evidence for transcatheter therapies.
Slides | tctmd.com
Apr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
Sep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the ICU (28% vs 13%; P = 0.038). However ...
When the Time Comes to Stop Oral Anticoagulation: Options and …
Sep 28, 2021 · Published in 2019, the analysis estimates the net clinical benefit of oral anticoagulation beyond age 75 in patients with AF, showing that the benefits become marginal after age 87 for warfarin and after age 92 for apixaban (Eliquis; Bristol-Myers Squibb). It shows “that we really need personalized and individualized decision-making where if ...
TCT 2024 - TCTMD.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose
Mar 12, 2020 · In A-fib patients selected using established dose-reduction criteria, the 2.5-mg twice daily dose of apixaban (Eliquis; Bristol-Myers Squibb) provides protection against stroke and death versus warfarin that is consistent with the effects of the standard 5.0-mg twice daily dose in the rest of the patients, despite reduced exposure to …
JenaValve™ reports significant clinical milestone: first-ever ...
Jan 18, 2011 · WILMINGTON, Del., USA, and MUNICH, JenaValve Technology, Inc., a medical device company specializing in developing transcatheter aortic valve implantation (TAVI) systems, announced today a significant clinical milestone the first ever successful transcatheter implantation of a 27mm transapical aortic valve prosthesis.
St. Jude Medical Furthers the Company’s Legacy of Heart Valve ...
May 16, 2016 · ST. PAUL, Minn., St. Jude Medical, Inc., a global medical device company, today announced the U.S. launch of the company’s most advanced tissue valve — the Trifecta™ valve with Glide™ Technology (GT) — for the treatment of patients diagnosed with unhealthy, damaged or malfunctioning aortic heart valves.Designed with feedback from a cohort of international physicians, the Trifecta GT ...
Thoratec Announces Start Of Heartmate III™ U.S. Clinical Trial
Sep 9, 2014 · The HeartMate III U.S. clinical trial is a randomized non-inferiority study comparing HeartMate III with HeartMate II®™ and includes a primary endpoint of survival free of device replacement and debilitating stroke. The trial began enrollment in a safety phase under conditional approval from the FDA for 30 patients at five sites.
New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides
Aug 21, 2019 · For managing hypertriglyceridemia (200-499 mg/dL), the AHA experts state that prescription-strength omega-3 fatty acids, either with eicosapentaenoic acid (EPA) or EPA plus docosapentaenoic acid (DHA), would be expected to yield a 20% to 30% reduction in triglycerides without any increase in LDL cholesterol.